Effect of tacrolimus on activity and expression of P-glycoprotein and ATP-binding cassette transporter A5 (ABCA5) proteins in hematoencephalic barrier cells.

@article{Quezada2008EffectOT,
  title={Effect of tacrolimus on activity and expression of P-glycoprotein and ATP-binding cassette transporter A5 (ABCA5) proteins in hematoencephalic barrier cells.},
  author={Claudia Quezada and Wallys Ximena Garrido and Mauricio Alejandro Gonz{\'a}lez-Oyarz{\'u}n and Mar{\'i}a Cecilia Rauch and M{\'o}nica Roxana Salas and Rody Enrique San Mart{\'i}n and Alejandro Andr{\'e}s Claude and Alejandro J Y{\'a}{\~n}ez and Juan Carlos Slebe and Juan G C{\'a}rcamo},
  journal={Biological & pharmaceutical bulletin},
  year={2008},
  volume={31 10},
  pages={1911-6}
}
Tacrolimus is an agent used in clinical immunosuppressive drug therapies. A wide spectrum of adverse effects has been reported in association with this immunosuppressor, including neurotoxic effect. The upper limit of therapeutic blood concentrations of tacrolimus has been described as 30 ng/ml in immunosuppressed patients. We investigated the effect of this therapeutic dose of tacrolimus on the expression and activity of the multidrug resistance protein 1 (MDR1 or Pgp, P-glycoprotein) and ATP… CONTINUE READING